Oak E - Search Results

1

Predictive factors and outcomes for ibrutinib therapy in relapsed/refractory mantle cell lymphoma-a "real world" study.

Epperla N, Hamadani M, Cashen AF, Ahn KW, Oak E, Kanate AS, Calzada O, Cohen JB, Farmer L, Ghosh N, Tallarico M, Nabhan C, Costa LJ, Kenkre VP, Hari PN, Fenske TS. Epperla N, et al. Among authors: oak e. Hematol Oncol. 2017 Dec;35(4):528-535. doi: 10.1002/hon.2380. Epub 2017 Jan 8. Hematol Oncol. 2017. PMID: 28066928

2

De novo CD5+ diffuse large B-cell lymphoma: Adverse outcomes with and without stem cell transplantation in a large, multicenter, rituximab treated cohort.

Alinari L, Gru A, Quinion C, Huang Y, Lozanski A, Lozanski G, Poston J, Venkataraman G, Oak E, Kreisel F, Park SI, Matthews S, Abramson JS, Iris Lim H, Martin P, Cohen JB, Evens A, Al-Mansour Z, Singavi A, Fenske TS, Blum KA. Alinari L, et al. Among authors: oak e. Am J Hematol. 2016 Jun;91(4):395-9. doi: 10.1002/ajh.24299. Am J Hematol. 2016. PMID: 26800311 Free PMC article.

3

Minimal activity of nanoparticle albumin-bound (nab) paclitaxel in relapsed or refractory lymphomas: results of a phase-I study.

Goyal S, Oak E, Luo J, Cashen AF, Carson K, Fehniger T, DiPersio J, Bartlett NL, Wagner-Johnston ND. Goyal S, et al. Among authors: oak e. Leuk Lymphoma. 2018 Feb;59(2):357-362. doi: 10.1080/10428194.2017.1330954. Epub 2017 Jun 9. Leuk Lymphoma. 2018. PMID: 28597723 Clinical Trial.

4

Blinatumomab for the treatment of B-cell lymphoma.

Oak E, Bartlett NL. Oak E, et al. Expert Opin Investig Drugs. 2015 May;24(5):715-24. doi: 10.1517/13543784.2015.1021415. Epub 2015 Mar 4. Expert Opin Investig Drugs. 2015. PMID: 25739952 Review.

5

Outcomes with R-CEOP for R-CHOP-ineligible patients with diffuse large B-cell lymphoma are highly dependent on cell of origin defined by Hans criteria.

Rashidi A, Oak E, Carson KR, Wagner-Johnston ND, Kreisel F, Bartlett NL. Rashidi A, et al. Among authors: oak e. Leuk Lymphoma. 2016 May;57(5):1191-3. doi: 10.3109/10428194.2015.1096356. Epub 2015 Oct 20. Leuk Lymphoma. 2016. PMID: 26397936 No abstract available.

6

Maintenance rituximab every 2 months is more toxic than every 3 months in patients with non-Hodgkin lymphoma.

Rashidi A, Oak E, Bartlett NL. Rashidi A, et al. Among authors: oak e. Blood. 2015 May 21;125(21):3354-5. doi: 10.1182/blood-2015-02-628362. Blood. 2015. PMID: 25999445 Free article. No abstract available.

7

A safety evaluation of brentuximab vedotin for the treatment of Hodgkin lymphoma.

Oak E, Bartlett NL. Oak E, et al. Expert Opin Drug Saf. 2016 Jun;15(6):875-82. doi: 10.1080/14740338.2016.1179277. Epub 2016 May 5. Expert Opin Drug Saf. 2016. PMID: 27139729 Review.

8

Impact of brushing with charcoal on tooth color and enamel loss: An in vitro study.

Rashid S, Hendren J, Elgendy H, Oak E, Shahinian C, Gabriel A, ElSalhy M. Rashid S, et al. Among authors: oak e. Am J Dent. 2022 Jun;35(2):133-136. Am J Dent. 2022. PMID: 35798707

9

Vitamin D modulates human macrophage response to Mycobacterium tuberculosis DNA.

Cervantes JL, Oak E, Garcia J, Liu H, Lorenzini PA, Batra D, Chhabra A, Salazar JC, Roca X. Cervantes JL, et al. Among authors: oak e. Tuberculosis (Edinb). 2019 May;116S:S131-S137. doi: 10.1016/j.tube.2019.04.021. Epub 2019 May 3. Tuberculosis (Edinb). 2019. PMID: 31085128 Free PMC article.

10

A Minority Report for Social Work? The Predictive Risk Model (PRM) and the Tuituia Assessment Framework in addressing the needs of New Zealand's Vulnerable Children.

Oak E. Oak E. Br J Soc Work. 2016 Jul;46(5):1208-1223. doi: 10.1093/bjsw/bcv028. Epub 2015 Apr 15. Br J Soc Work. 2016. PMID: 27559223 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

11 results

Search Page